Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. This news page aggregates company press releases, clinical updates, financial disclosures, and corporate announcements so readers can follow how Fate Therapeutics’ iPSC-derived CAR T-cell and NK-cell programs progress over time.
Recent news from Fate Therapeutics has highlighted updated Phase 1 clinical data for FT819, its off-the-shelf CD19-targeted CAR T-cell product candidate for systemic lupus erythematosus (SLE), including reports of sustained reductions in disease activity scores, B-cell depletion with immune remodeling, and a favorable safety profile with less-intensive or no conditioning chemotherapy. The company has also issued news on regulatory authorizations to expand FT819 trials into the United Kingdom and European Union, initiation of dose-expansion cohorts in additional autoimmune diseases, and presentations at major medical meetings such as the American College of Rheumatology (ACR) Convergence and the American Society of Hematology (ASH) Annual Meeting.
In oncology, Fate Therapeutics’ news flow includes updates on FT825 / ONO-8250 for advanced HER2-positive solid tumors and FT836, a MICA/B-targeted CAR T-cell program being evaluated without conditioning chemotherapy, as well as preclinical progress on FT839, a dual CAR T-cell candidate co-targeting CD19 and CD38. Investors can also find quarterly financial results, details of corporate restructuring to streamline operations and extend cash runway, and information on executive appointments and employee inducement equity awards.
By reviewing the FATE news feed, readers can track clinical milestones, regulatory interactions, conference presentations, and corporate developments that shape the company’s iPSC-derived cell therapy pipeline. Bookmark this page for a consolidated view of Fate Therapeutics’ latest publicly released information.
Fate Therapeutics (NASDAQ: FATE) said the FDA selected its off-the-shelf iPSC-derived anti-CD19 CAR T candidate FT819 for the CMC Development and Readiness Pilot (CDRP) program to support manufacturing readiness for SLE with lupus nephritis.
Selection and existing RMAT designation aim to accelerate CMC engagement and help align manufacturing readiness with a planned Phase 2 potentially registrational trial.
Fate Therapeutics (NASDAQ: FATE) will present clinical and preclinical data from its off-the-shelf CAR T-cell pipeline at the 2026 ASGCT Annual Meeting in Boston, May 11–15, 2026. Presentations cover FT819 SLE data without conditioning chemotherapy, an oral on dual-targeting FT839, and preclinical FT836 MICA/B tumor data.
Key sessions: FT819 poster May 12, FT836 poster May 13, and FT839 oral May 14. The programs focus on iPSC-derived, off-the-shelf CAR T approaches for autoimmune and oncology indications.
Fate Therapeutics (NASDAQ: FATE) granted 30,200 restricted stock units (RSUs) on May 1, 2026 to one newly hired non-executive employee as an inducement under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The grant was approved by the Compensation Committee. The RSUs vest over four years, with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) will present clinical data for its off-the-shelf CAR T candidate FT819 at CCR–East 2026 (Destin, FL; Apr 30–May 3, 2026).
Presentation covers safety, efficacy, and translational results from 13 SLE patients (data cutoff Dec 23, 2025), including SLEDAI-2K −13 points at Month 6 and substantial FACIT-Fatigue improvements after a single FT819 dose with reduced conditioning.
Fate Therapeutics (NASDAQ: FATE) will present preclinical data for its next‑generation off‑the‑shelf CAR T candidate FT839 at the AACR Annual Meeting, April 17–22, 2026 in San Diego.
FT839 is described as a 13‑point edited, dual‑CAR product targeting CD19 and CD38, using Sword and Shield™ technology to evade host immune responses and potentially remove the need for conditioning chemotherapy. Poster: April 21, 2026, 9:00 a.m.–Noon PDT.
Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.
- April 14 — Needham Virtual Healthcare Conference (virtual)
- May 13 — Bank of America Healthcare Conference, Las Vegas
- May 19 — H.C. Wainwright BioConnect, New York
- June 4 — Jefferies Global Healthcare, New York
- June 10 — Goldman Sachs Global Healthcare, Miami Beach
The company said presentations or fireside chats may occur and live webcasts will be available under Events & Presentations on the company website, with archived replays accessible for 30 days.
Fate Therapeutics (NASDAQ: FATE) granted 7,260 restricted stock units (RSUs) on April 1, 2026 to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved the award under the companys Amended and Restated Inducement Equity Plan.
The RSUs vest over four years with 25% vesting on each anniversary, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) granted restricted stock units representing 50,700 shares to three newly hired non-executive employees on March 2, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The awards vest over four years with 25% vesting on each anniversary, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.
Fate Therapeutics (NASDAQ: FATE) reported Q4 and full-year 2025 results and clinical progress on Feb 26, 2026. The company ended 2025 with $205.1 million in cash, projects runway through year-end 2027, and recorded Q4 revenue of $1.4 million. FT819 achieved outpatient dosing across autoimmune indications (15 SLE, 4 SSc, 1 IIM treated) and showed a 3-month improvement in a systemic sclerosis patient. FT836 showed a >50% CEA reduction in a CRC patient without conditioning chemotherapy. Operating expenses declined ~30% in 2025 versus 2024.